Neither metformin nor sitagliptin have the potential to inhibit or induce CYP enzymes. No porphyrinogenic physiological effects. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition and motivates attendance.

Metformin and sitagliptin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition intake.

Metformin: Not a Cyp-substrate. Sitagliptin: Approximately 79 per cent of sitagliptin is excreted unchanged in the urine. Nonclinical studies indicate that the small portion of sitagliptin that undergoes biotransformation is metabolized by Cyp3A4 with the help of Cyp2C8. In vitro data has shown that sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2Experiental and clinical data indicate that there is low risk for pharmacokinetic interactions with Cyp-metabolized drugs.

Metformin (ATC code: A10BA02) 30 reports of uneventful use. Sitagliptin: No EPNET drug reports.